Company profile
Kane Biotech Inc.
OTC: KNBIF · Healthcare · Biotechnology
Canadian filerHQ Winnipeg, MBReports USD
#972 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
24DFH 23DQ —GM 13SS 51
v0.1 · 45/100 weight · provisional
↑ listing tenure, disclosure history · ↓ Piotroski F, revenue growth (YoY)
Methodology →Revenue TTM
$28.2k
Rev growth YoY (TTM)
-97.9%
Net income (FY)
-$1.9M
Employees
20
as of 2026-08-24
Market cap
$4.5M
as of 2026-08-24
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$305.8k427.5k CAD2025
Net income-$1.9M-2.7M CAD2025
Operating income-$2.2M-3.1M CAD2025
Total assets$2.0M2.7M CAD2025
Liabilities$2.5M3.5M CAD2025
Equity-$544.2k-745.9k CAD2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Kane Biotech Inc.’s revenue?
Kane Biotech Inc. booked $305.8k in FY2025 revenue, contracting 80% year over year — slower than 88% of Healthcare companies we track, at a -636.0% net margin.
Peers · Healthcare
Interactive Health Network——Medixall Group, Inc.——Atai Beckley Inc.——Cannabis Bioscience International Holdings, Inc.18DNexalin Technology, Inc.34DBioAtla, Inc.15DKey facts
CEORobert Huizinga
SectorHealthcare
IndustryBiotechnology
HeadquartersWinnipeg, MB
ExchangeOTC: KNBIF
Employees20
IPO date2007-08-07
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.